Drugs / PF-04802540
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00876304 | Apr → Sep 2009 | schizophrenia | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00772512 | Nov 2008 → Feb 2009 | — | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00756743 | Sep 2008 → Jan 2009 | — | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-04802540 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00772512 ↗ |
| Route | Oral | “administered orally” NCT00756743 ↗ |